Loading...
Market
How much will Siemens Healthineers' market share in the molecular imaging sector increase by the end of 2025 due to the acquisition of Novartis' Molecular Imaging Business?
2
Resolution / Starting Odds
Increase by more than 5% • 25%
Increase by 2-5% • 25%
Increase by less than 2% • 25%
No significant increase • 25%
Industry reports from market research firms such as Gartner or IDC
Story
Siemens Healthineers to Acquire Novartis' Molecular Imaging Business in $224 Million Deal
Aug 26, 2024, 12:36 PM
Siemens Healthineers has agreed to acquire a part of Novartis' business specializing in radioactive chemicals used for cancer scans. The $224 million deal involves the molecular imaging business for Fluorine-18 positron emission tomography (PET) scans. This acquisition is expected to further boost Siemens Healthineers' healthcare operations. Novartis confirmed receiving a binding offer from Siemens Healthineers for this acquisition.
View original story
Similar markets
0-10% • 25%
11-20% • 25%
21-30% • 25%
31%+ • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Increase by 5% or more • 33%
Fluctuate within ±5% • 33%
Decrease by 5% or more • 33%
Market share increases • 25%
Market share remains the same • 25%
Market share decreases • 25%
Foresight exits cancer-detection market • 25%
Below 5% • 25%
5%-10% • 25%
10%-15% • 25%
Above 15% • 25%
Less than 5% • 25%
5% to 10% • 25%
10% to 15% • 25%
More than 15% • 25%
Less than 10% • 33%
10% to 25% • 33%
More than 25% • 33%
Less than 20% • 25%
20-40% • 25%
41-60% • 25%
More than 60% • 25%
Less than 5% • 25%
5% - 10% • 25%
10% - 15% • 25%
More than 15% • 25%
0-10% • 25%
11-25% • 25%
26-50% • 25%
51%+ • 25%
Less than 5% • 25%
5% to 10% • 25%
10% to 20% • 25%
More than 20% • 25%
More than 25% • 25%
Between 15% and 25% • 25%
Between 5% and 15% • 25%
Less than 5% • 25%